SI3139948T1 - Zdravljenje diabetesa tipa 1 z uporabo GLP-1 in anti-IL-21 - Google Patents

Zdravljenje diabetesa tipa 1 z uporabo GLP-1 in anti-IL-21

Info

Publication number
SI3139948T1
SI3139948T1 SI201531210T SI201531210T SI3139948T1 SI 3139948 T1 SI3139948 T1 SI 3139948T1 SI 201531210 T SI201531210 T SI 201531210T SI 201531210 T SI201531210 T SI 201531210T SI 3139948 T1 SI3139948 T1 SI 3139948T1
Authority
SI
Slovenia
Prior art keywords
glp
treatment
diabetes type
diabetes
type
Prior art date
Application number
SI201531210T
Other languages
English (en)
Inventor
Ken Coppieters
Herrath Matthias Von
Tamar Boursalian
Original Assignee
Novo Nordisk A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk A/S filed Critical Novo Nordisk A/S
Publication of SI3139948T1 publication Critical patent/SI3139948T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
SI201531210T 2014-05-07 2015-05-05 Zdravljenje diabetesa tipa 1 z uporabo GLP-1 in anti-IL-21 SI3139948T1 (sl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201461989841P 2014-05-07 2014-05-07
EP14169596 2014-05-23
EP14189732 2014-10-21
EP15720982.6A EP3139948B1 (en) 2014-05-07 2015-05-05 Treatment of diabetes type 1 using glp-1 and anti-il-21
PCT/EP2015/059811 WO2015169789A1 (en) 2014-05-07 2015-05-05 Treatment of diabetes type 1 using glp-1 and anti-il-21

Publications (1)

Publication Number Publication Date
SI3139948T1 true SI3139948T1 (sl) 2020-07-31

Family

ID=54392180

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201531210T SI3139948T1 (sl) 2014-05-07 2015-05-05 Zdravljenje diabetesa tipa 1 z uporabo GLP-1 in anti-IL-21

Country Status (9)

Country Link
US (1) US10105442B2 (sl)
EP (1) EP3139948B1 (sl)
JP (1) JP6672175B2 (sl)
CN (1) CN106999553B (sl)
PL (1) PL3139948T3 (sl)
RS (1) RS60316B1 (sl)
SI (1) SI3139948T1 (sl)
TW (1) TWI668010B (sl)
WO (1) WO2015169789A1 (sl)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108883159A (zh) * 2016-03-04 2018-11-23 诺和诺德股份有限公司 用于糖尿病性足溃疡的利拉鲁肽

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA72181C2 (uk) 1996-08-30 2005-02-15 Ново Нордіск А/С Похідна глюкагоноподібного пептиду-1 (варіанти), фармацевтична композиція та спосіб одержання лікувального засобу (варіанти), спосіб лікування діабету (варіанти) і ожиріння
US7186683B2 (en) 2000-09-18 2007-03-06 Sanos Bioscience A/S Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders
EP1412384B1 (en) * 2001-06-28 2007-12-26 Novo Nordisk A/S Stable formulation of modified glp-1
ES2629395T3 (es) * 2001-10-04 2017-08-09 Genetics Institute, Llc Métodos y composiciones para modular la actividad de la interleucina-21
WO2003105897A1 (en) 2002-06-14 2003-12-24 Novo Nordisk A/S Combined use of a modulator of cd3 and a glp-1 compound
WO2005023291A2 (en) * 2003-09-11 2005-03-17 Novo Nordisk A/S Use of glp1-agonists in the treatment of patients with type i diabetes
CN100444898C (zh) * 2003-09-19 2008-12-24 诺沃挪第克公司 治疗肽的清蛋白结合型衍生物
ATE498404T1 (de) * 2003-12-09 2011-03-15 Novo Nordisk As Regulierung der nahrungspräferenz mit glp-1- agonisten
EP1841448A2 (en) 2004-12-30 2007-10-10 Diakine Therapeutics, Inc. Pharmaceutical compositions and methods for restoring beta-cell mass and function
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
US7393919B2 (en) 2005-05-25 2008-07-01 Cure Dm, Inc. Peptides, derivatives and analogs thereof, and methods of using same
EP2441460A1 (en) * 2005-06-30 2012-04-18 Ipsen Pharma GLP-1 pharmaceutical compositions
CA2658678A1 (en) 2005-08-06 2007-02-15 Gerald J. Prud'homme Composition and method for prevention and treatment of type i diabetes
CN101291685A (zh) * 2005-08-19 2008-10-22 安米林药品公司 治疗糖尿病和降低体重的毒蜥外泌肽
EP2347762B1 (en) 2005-08-19 2019-05-08 Amylin Pharmaceuticals, LLC Exendin for treating diabetes and reducing body weight
US8084022B2 (en) * 2006-06-23 2011-12-27 Aegis Therapeutics, Llc Stabilizing alkylglycoside compositions and methods thereof
US20100179131A1 (en) * 2006-09-07 2010-07-15 Nycomed Gmbh Combination treatment for diabetes mellitus
WO2008145137A2 (en) * 2007-05-31 2008-12-04 Genmab A/S Recombinant non glycosylated monovalent half-antibodies obtained by molecular engineering
NZ599756A (en) * 2007-08-30 2013-09-27 Curedm Group Holdings Llc Compositions and methods of using proislet peptides and analogs thereof
EP2679597A1 (en) * 2007-09-05 2014-01-01 Novo Nordisk A/S Glucagon-like peptide-1 derivatives and their pharmaceutical use
US7883700B2 (en) * 2007-12-07 2011-02-08 Zymogenetics, Inc. Anti-human IL-21 monoclonal antibodies
US20090280169A1 (en) * 2008-05-07 2009-11-12 Merrion Research Iii Limited Compositions of peptides and processes of preparation thereof
CA2953975C (en) * 2008-06-27 2019-11-26 Duke University Therapeutic agents comprising elastin-like peptides
PE20121362A1 (es) * 2009-11-13 2012-10-17 Sanofi Aventis Deutschland Composicion farmaceutica que comprende despro36exendina-4(1-39)-lys6-nh2, insulina gly(a21)-arg(b31)-arg(b32) y metionina
EP2359843A1 (en) * 2010-01-21 2011-08-24 Sanofi Pharmaceutical composition for treating a metabolic syndrome
JP2013520208A (ja) 2010-02-24 2013-06-06 ザ・ボード・オブ・トラスティーズ・オブ・ザ・レランド・スタンフォード・ジュニア・ユニバーシティ 自己免疫疾患の診断、予後判定、及び処置法
US20130323259A1 (en) 2011-01-17 2013-12-05 Novo Nordisk A/S Il-21 ligands
US8822417B2 (en) * 2011-05-05 2014-09-02 Novozymes Biopharma DIC A/S Albumin variants
WO2012164021A1 (en) * 2011-05-31 2012-12-06 Novo Nordisk A/S Il-21 epitope and il-21 ligands
EP2746293A1 (en) 2012-12-21 2014-06-25 Novo Nordisk A/S Anti-IL21 antibodies for use in the treatment of cardiovascular diseases
EP2746292A1 (en) 2012-12-21 2014-06-25 Novo Nordisk A/S Anti-IL21 antibodies for use in the treatment of nephropathies

Also Published As

Publication number Publication date
US20170043014A1 (en) 2017-02-16
WO2015169789A1 (en) 2015-11-12
RS60316B1 (sr) 2020-07-31
EP3139948A1 (en) 2017-03-15
TW201625289A (zh) 2016-07-16
TWI668010B (zh) 2019-08-11
JP2017514860A (ja) 2017-06-08
CN106999553A (zh) 2017-08-01
US10105442B2 (en) 2018-10-23
JP6672175B2 (ja) 2020-03-25
EP3139948B1 (en) 2020-03-04
PL3139948T3 (pl) 2020-08-10
CN106999553B (zh) 2021-11-26

Similar Documents

Publication Publication Date Title
HRP20190369T1 (hr) Spojevi dihidrobenzofurana koji su korisni u liječenju dijabetesa i pretilosti
HK1243073A1 (zh) 治療性化合物及其用途
IL246757B (en) New insulin histories and their medical uses
PT3297653T (pt) Tratamento de hipoglicemia pós-bariátrica com antagonistas de glp-1
IL283335B (en) Dihydropyrimidine-2-one compounds and their medical use
HK1244216A1 (zh) 治療2型糖尿病患者
GB201612165D0 (en) Combinations for the treatment of type 2 diabetes
HK1251449A1 (zh) 用於治療2型糖尿病的交聯聚二烯丙基胺共聚物
IL254500A0 (en) Treatment of patients with type 2 diabetes
GB201403996D0 (en) Traditional chinese medicine composition for the treatment of diabetes
HK1244821A1 (zh) 用於治療和診斷1型糖尿病中使用的肽
GB201707207D0 (en) Treatment of type 1 diabetes
RS60316B1 (sr) Lečenje dijabetesa tipa 1 korišćenjem glp-1 i anti-il-21
HK1257593A1 (zh) 治療糖尿病的新藥物及其用途
IL250666B (en) A peptide for the treatment of diabetes mellitus type 2 and its complications
PT3139948T (pt) Tratamento de diabetes usando glp-1 e anti-il-21
GB201513543D0 (en) Compositions for use in the treatment of diabetes
GB201418541D0 (en) Materials for use with general hyperthermia treatment
SG10201400823PA (en) Therapeutic methods and compositions for treating diabetes
GB201417777D0 (en) Novel compounds and therapeutic uses thereof